{"id":"103b4b6d78f6","type":"article","url":"https://hartvaat.nl/2025/01/01/aficamten-en-de-toekomst-van-obstructieve-hcm-behandeling/","title":"Aficamten en de toekomst van obstructieve HCM-behandeling","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103343?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725103343?dgcid=rss_sd_all","authors":["Sara Saberi"],"significance":6,"published":"2026-03-25","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This JACC editorial outlines how aficamten may fundamentally change the treatment of obstructive hypertrophic cardiomyopathy. It places recent trial results in the context of the evolving therapeutic landscape, including the relationship to mavacamten and surgical myectomy.","created":"2026-07-03T10:32:38Z","updated":"2026-07-03T13:31:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit JACC-editorial schetst hoe aficamten de behandeling van obstructieve hypertrofische cardiomyopathie fundamenteel kan veranderen. Het stuk plaatst de recente trialresultaten in het perspectief van het evoluerend therapeutisch landschap, inclusief de relatie tot mavacamten en chirurgische myectomie.","abstract_original":"Publication date: 3 March 2026Source: JACC, Volume 87, Issue 8"}